ADPT

In the past six months, ADPT's stock has been impacted by strong financial results for Q1 2026, exceeding forecasts by approximately 16.4%, primarily driven by its Minimal Residual Disease (MRD) business. Adaptive Biotechnologies also raised its full-year 2026 MRD revenue guidance to between $260 million and $270 million. In February 2026, the company reported strong execution and progress in 2025, with 46% revenue growth and profitability in its MRD business. Insider trading activity has also been noted, with the Chief Operating Officer selling over 19,000 company shares in April 2026 as part of a Rule 10b5-1 trading plan. The stock price has shown volatility, moving 11% a week, but ADPT outperformed the US Life Sciences industry and the broader US market over the past year.